Goodman Advisory Group LLC Makes New $1.87 Million Investment in Insulet Corporation $PODD

Goodman Advisory Group LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,560 shares of the medical instruments supplier’s stock, valued at approximately $1,865,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Deutsche Bank AG grew its position in Insulet by 33.9% in the 4th quarter. Deutsche Bank AG now owns 308,447 shares of the medical instruments supplier’s stock worth $87,673,000 after purchasing an additional 78,096 shares in the last quarter. GW&K Investment Management LLC grew its position in Insulet by 40.1% in the 4th quarter. GW&K Investment Management LLC now owns 346 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 99 shares in the last quarter. Winnow Wealth LLC grew its position in Insulet by 10.0% in the 4th quarter. Winnow Wealth LLC now owns 3,067 shares of the medical instruments supplier’s stock worth $874,000 after purchasing an additional 278 shares in the last quarter. Cerity Partners LLC grew its position in Insulet by 5.4% in the 4th quarter. Cerity Partners LLC now owns 13,206 shares of the medical instruments supplier’s stock worth $3,754,000 after purchasing an additional 679 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Insulet in the 4th quarter worth about $6,268,000.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PODD shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Truist Financial dropped their target price on shares of Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. BTIG Research dropped their target price on shares of Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, May 26th. Finally, Robert W. Baird dropped their target price on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $250.00.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.36% of the company’s stock.

Insulet Stock Down 5.6%

PODD opened at $150.71 on Thursday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The stock has a market cap of $10.44 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 1.26 and a beta of 1.13. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company’s 50-day moving average price is $172.28 and its two-hundred day moving average price is $234.54.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period last year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.